We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Physician Office IVD Sector Nears USD 2.5 Billion

By LabMedica International staff writers
Posted on 14 Sep 2014
The physician office laboratory (POL) in vitro diagnostic (IVD) market grew to USD 2.44 billion in 2013, from just over USD 2 billion four years ago, according to the 2014 market study report “Physician Office Laboratory Markets, 3rd Edition” from Kalorama Information (New York, NY, USA). More...
Considered in its POL analysis are tests physically performed in a physician office setting or lab located on the premises of the clinic or practice (not an associated hospital), and performed at the time of a consultation with a physician or other healthcare professional for screening, diagnosis, or monitoring purposes.

Physician Office Laboratory Markets reveals that unlike laboratory medicine (or lab pathology), there is no settled role for professional point-of-care (POC) or “near-patient” testing (NPT) in modern healthcare systems. The use of decentralized IVD testing in primary and outpatient care, most often in POLs, is not uniform worldwide nor is it universally supported. Nonetheless, payers, regulators, and administrators are forced to address POL testing as capabilities of benchtop and portable IVD instruments and assays improve and present clinicians with more in-house testing options.

"Gone are the days when professional POC diagnostics markets could aspire to above-average annual revenue on the basis of market penetration and the rising profile of decentralized testing," said Emil Salazar, analyst for Kalorama Information and author of the report, "The overall POL market is instead projected over the next 5 years to average growth near equal with the overall global IVD market."

The POL market features numerous in-office tests that have been widely implemented due to the low hurdles presented by CLIA-waived testing and the value of core lab tests performed in-office at large practices and with specialists. Some POL test segments are expected to see average annual growth through 2019 of only 0%–1%. POL test segments projected to attract more growth (rates of 5% and over) are related to diabetes care, cardiovascular disease, and actionable infectious disease markers. Routine infectious disease testing has also invited the first forays of molecular diagnostics into the POL space.

The prospects of POL market growth also vary widely by geography. Kalorama Information has profiled the traditionally core country markets for POL tests and determined their future potential in light of recent regulatory tightening of fee schedules and reimbursement eligibility as well as other factors. In some cases, recent regulation threatens to tip competitive balance even more towards higher-volume labs, typically reference or commercial labs, across from smaller labs including POLs.

Physician Office Laboratory Markets not only presents leading opportunities for IVD sales growth in the POL channel, but is also a valuable resource for determining competitive positioning within the channel vis-à-vis its leading players.

Related Links:

Kalorama Information



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.